New Heart Device Enters Clinical Trial in Columbus
The device could simplify treatment for patients with recurrent ventricular tachycardia by performing mapping and ablation.
Updated on Oct. 29, 2026 in Heart Disease
Live Poll
Do you believe new medical device trials generally lead to better health outcomes for patients?
Ohio State Wexner Medical Center has become the first site in the Midwest to enroll a patient in the Sphere-9 clinical trial. The study evaluates a new catheter device designed to treat recurrent ventricular tachycardia by performing heart mapping and treatment without needing device exchanges.
Why it matters
Recurrent ventricular tachycardia is a life-threatening condition that requires highly effective intervention. This trial tests whether a new, more efficient catheter design can simplify the ablation process to improve outcomes for patients with this rhythm disorder.
This clinical trial is evaluating a device that recently received FDA breakthrough designation to treat recurrent ventricular tachycardia. The trial is currently ongoing, and the clinical efficacy of this combined mapping and ablation technology has not yet been fully established.
The players
Ohio State Wexner Medical Center
A major academic medical center specializing in advanced cardiovascular care and clinical research.
Medtronic
A global medical technology company that develops cardiovascular devices and rhythm management systems.
The details
The experimental catheter allows electrophysiologists to perform heart mapping, rhythm verification, and ablation using a single device. By integrating both radiofrequency and non-thermal pulsed electric field energy, the system is designed to destroy abnormal heart tissue causing the arrhythmia more efficiently. The procedure utilizes a Medtronic-manufactured mapping system to provide precise guidance during the intervention.
Timeline
2020: Ohio State first used pulsed field ablation technology.
April 2026: FDA granted breakthrough device designation.
October 16, 2026: Ohio State physician performed the procedure.
October 28, 2026: Trial enrollment at Ohio State reported.
Health Landscape
This trial represents a shift toward more streamlined cardiac ablation procedures that combine multiple energy modalities in one device. It follows the FDA breakthrough device designation program, which is designed to accelerate the development of technologies for life-threatening conditions.
This trial highlights ongoing efforts to refine treatment for dangerous heart rhythm disorders like ventricular tachycardia. Patients with these conditions should discuss their current management plan and potential new treatment options with their cardiologist to determine if a trial is relevant.
The takeaway
The development of integrated catheter technology may lead to more efficient and effective procedures for patients with recurrent heart rhythm issues. If you are managing a condition like ventricular tachycardia, speak with your physician about the latest clinical trial options in your area.
Further reading
For more on managing heart rhythm disorders, visit our guide on Heart Disease.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe new medical device trials generally lead to better health outcomes for patients?
